There are 850,000 people with dementia in the UK, according to the Alzheimer’s Society. This figure is set to to over one million by 2025 and two million by 2051. Dementia is the term used to describe different brain disorders that trigger a loss of brain function. Alzheimer’s disease is the most common type of dementia, affecting 62 per cent of those diagnosed.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs